80.00 +0.98 (1.24%)
Pre-Market: 7:19AM EST
|Bid||79.76 x 100|
|Ask||80.00 x 100|
|Day's Range||78.65 - 79.40|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||8.99|
|Forward Dividend & Yield||2.08 (2.63%)|
|1y Target Est||N/A|
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years. It expects to witness a major turnaround of its business with the implementation of this plan.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.
In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.
Pfizer Inc. (NYSE:PFE) has been rather quietly churning higher. Over the last six months, Pfizer stock is up nearly 10% and it hit new highs in December. With a dividend yield of 3.75% and a low valuation, many investors are content holding shares of PFE.
In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall and a 26.8% reported fall year-over-year (or YoY). The company reported HCV sales of close to $60 million from the US market in 3Q17, a YoY fall of ~19.5%. AbbVie also reported HCV sales of close to $216 million from international markets in 3Q17, a YoY fall of 29.8% on an operational basis and a fall of 28.7% on a reported basis.
Gilead Sciences (GILD) is changing its stripes. BMO Capital Markets' M. Ian Somaiya, for one contends that the stock is more "intriguing" as its focus shifts away from anti-virals. Somaiya argues that more predictable HCV sales, along with a strong launch of its HIV treatment bictegravir and non-Hodgkin lymphoma drug Yescarta are crucial for Gilead's new, more diverse, identity.
On December 14, 2017, Teva (TEVA) stock gained more than 10% on the back of the announcement of a comprehensive restructuring plan and additional measures to improve the company’s operational and financial performance. On December 14, 2017, the Generic Drugs ETF (GNRX) rose by approximately 1.0%. Teva Pharmaceuticals has a debt of $32 billion, which needs to be serviced in an organized manner to strengthen the company’s financials and bring down leverage.
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.
This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.
On December 27, 2017, Teva Pharmaceuticals (TEVA) announced the exclusive launch of the generic version of Reyataz, which is a registered trademark of Bristol-Myers Squibb (BMY) in the United States. The generic version of Reyataz is Teva’s fifth generic drug offering in the area of HIV-1 infection treatment. In fiscal 3Q17, the total generic products sales contributed approximately 54% to the company’s total sales as compared to 59% of the generics sales contribution in fiscal 3Q16.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has begun a turnaround. The Laval, Canada-based drug manufacturer is on a growth path again after VRX stock came crashing from lofty highs. A new CEO now works to drive profits and reduce a heavy debt burden.
As we discussed earlier, Ionis Pharmaceuticals (IONS) is one of the leading biopharmaceutical companies focused on discovering, developing, and commercializing RNA-targeted (ribonucleic acid) therapies. Ionis has created a drug discovery platform and developed many drugs for the treatment of various life-threatening diseases through this broadly applicable platform. Ionis’s revenue sources include its commercial revenue, including its Spinraza royalties and licensing and royalty revenues, and its research and development revenue under its collaborative agreements.